Innoviva Q2 2025 net income $63.7 million, up from a net loss a year earlier
Innoviva reported second quarter 2025 results on August 6, 2025. Total revenue was $100.3 million, up slightly from $99.9 million a year earlier, and the company swung to net income of $63.7 million, or $1.01 basic per share, from a net loss of $34.7 million. Income from operations fell 11% to $48.8 million, while favorable changes in investment fair values helped the bottom line.
Key points
- Total revenue of $100.3 million, compared with $99.9 million in Q2 2024
- Net income of $63.7 million, or $1.01 basic per share, versus a net loss of $34.7 million, or $(0.55) per share, a year earlier
- Income from operations of $48.8 million, down 11% from $54.7 million, partly due to zoliflodacin R&D costs
- U.S. net product sales of $29.0 million, up 54% from $18.8 million; zoliflodacin PDUFA date is December 15, 2025
The filing
Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.